Screen Shot 2021-06-24 at 16.50.06

WSJ features Ochre Bio: “Biotech Startup Ochre Bio Lands Seed Financing to Combat Liver Diseases”

Brian Gormley ⁦of The Wall Street Journal has featured Ochre Bio and their novel approach to tackling chronic liver disease (a top ten cause of death globally).

“We’re starting with a focus on improving outcomes for transplant patients, and are making exciting progress scientifically here in Oxford. With great investors onboard, a wonderful team coming together, and an international network of transplant / clinical partners – we are well on our way to developing life-saving medicines for one of the toughest healthcare challenges of our time” said Ochre Bio.

Screen Shot 2021-06-24 at 16.36.22

CogX Shortlists BIOS in their AI awards for Best Innovation in Pharma

We are thrilled to announce that BIOS was shortlisted for the “Best Innovation in Pharma” in this year’s CogX Awards.

The CogX Awards are the most exciting celebration of innovation and transformational opportunities in the world – a time to give the companies and individuals making a difference a platform.

This year, award categories are spread across six themes: Recognising Leadership, Best AI Product, Best Innovation, Outstanding Achievements & Research Contributions, Best Climate Innovation and Global Goals – with more than 60 individual categories covering verticals from AI to Global Leadership, Financial Services to Climate Change, and from GenZ to Covid-19 Response.

 

Screen Shot 2021-05-21 at 23.10.17

These Are The Top 101 Therapeutics Startups to Follow in 2021

This article showcases Startup Pill’s top picks for the best Therapeutics startups. These startups are taking a variety of approaches to innovating inside of the Therapeutics industry and around the world. They are all exceptional startups well worth a follow.

We tried to pick companies across the size spectrum from cutting edge startups to established brands.

We selected these startups for exceptional performance in one of these categories:

  • Innovation
    • Innovative ideas
    • Innovative route to market
    • Innovative product
  • Growth
    • Exceptional growth
    • Exceptional growth strategy
  • Management
  • Societal impact
Screen Shot 2021-05-21 at 23.03.34

Lyfebulb-CSL Behring Innovation Challenge: Thriving with Transplantation

The goal of the 2021 Lyfebulb-CSL Behring Innovation Challenge: Thriving with Transplantation is to source innovative solutions to improve outcomes and experiences for all those affected by transplantation.

The Innovation Challenge will take place virtually in May 2021 and is currently accepting applications through February 19, 2021. Patient entrepreneurs – those who have been affected by chronic disease as either a patient or support partner for a loved one and started a company to develop solutions to an unmet need identified in their disease journey – are encouraged to apply.

Selected finalists will receive an invitation to pitch their company’s solutions to an expert panel of judges comprised of healthcare industry, medical and patient leaders. One winner will be awarded a $25,000 monetary grant. Competing finalists may be considered for possible partnerships or investments beyond the challenge. Beyond presenting their innovative ventures, the finalists will have the opportunity to exchange ideas on how to further advance patient innovation in the transplant community; engage with Lyfebulb founders, CSL Behring leadership leadership, representatives from the patient community, key opinion leaders and potential investors; and share insights with each other.

The Lyfebulb-CSL Behring Innovation Challenge stems from the idea of the Lyfebulb Entrepreneur Circle, established in 2015, and features individuals who have created a product and a company based on the issues encountered due to their personal experiences with a chronic illness (through their own diagnosis or that of a loved one).

Dr_Camilla_Easter_CEO_of_Oxford_Medical_Products

Oxford Medical Products closes £1.2 million for weight loss technology

Oxford Medical Products (OMP) has raised £1.2M in seed investment to develop a safe and affordable weight loss capsule, which uses the same mechanism of action as a gastric balloon, but can be taken at home. The funding will be used to complete pre-clinical testing, upscale and outsource manufacturing and grow the team. The funding was led by Ada Ventures with Selvedge Venture alongside several angel investors including Dr Nick Edwards, a founder of the company, and Dr Jan Hruska, co-founder of Sophos.

image

OMP receives €1.3 million for Sirona self-expanding hydrogel weight loss capsule

Oxford Medical Products (OMP) has raised €1.3 million to develop a safe and affordable weight loss capsule, which uses the same mechanism of action as a gastric balloon, but can be taken at home. The funding will be used to complete pre-clinical testing, upscale and outsource manufacturing and develop the company’s workforce.

The company’s non-surgical weight loss technology Sirona, is a self-expanding hydrogel capsule that once swallowed expands in the stomach, reducing hunger and, the company claims, leading to significant weight loss. The capsules stay in the stomach for several weeks before breaking down gradually and passing naturally over time.

Oxford Medical Products was founded in 2017 by Professor Jan Czenurska a world-renowned expert in hydrogels, and Dr Hutan Ashrafian a pioneering bariatric surgeon – with Dr Camilla Easter and Dr Nick Edwards, two medically trained entrepreneurs, joining Oxford Medical Products soon after.

image

Healthtech startup Mesh Bio in Singapore raises $1.8 M in seed funding

Singapore-based healthtech startup Mesh Bio has raised $1.8 million (SGD2.4 million) in Seed funding, led by deep tech investors Elev8.vc and Enterprise Singapore’s investment arm Seeds Capital, along with Citrine Capital and Tael Partners.

The funds will be used to accelerate the rollout of Mesh Bio’s solution, DARA® – a predictive analytics and clinical workflow automation solution for healthcare providers – in Southeast Asia and Hong Kong. The funding will also support clinical partnerships and collaborations.

image

Mesh Bio raises US$1.8M seed to help doctors predict diseases before they occur

Mesh Bio, a Singaporean health-tech startup, has raised US$1.8 million in a seed funding round, led by deep-tech investor Elev8.vc and SEEDS capital.

Wealth management firm Citrine Capital as well as Singaporean VC firm Tael Partners also joined the round. 

Mesh Bio intends to use the capital to accelerate the rollout of its solution, DARA, for healthcare providers in Southeast Asia and Hong Kong. The funds will also support the startup’s clinical partnerships and collaborations.

Mesh Bio intends to expand its solution further across Southeast Asia and Hong Kong.

 

scaled_full_7e07221de65eada57742

Your Brain, With a USB Port in It: Elon Musk’s Neuralink Vision Divides Experts

Your brain, with a USB-C port in it. That’s Elon Musk’s vision for Brain Machine Interfaces (BMI). In a controversial July 2019 white paper he claimed that his company Neuralink had taken a huge step towards building a “scalable high-bandwidth BMI system” that would let the human brain “stream full broadband electrophysiology data” to a network, using a combination of ultra-fine polymer probes, a neurosurgical robot that sews them into the brain, and custom high-density electronics.